Publications and Presentations

2008

Chen J, Lam S, Pilon A, McWilliams A, MacAulay C, Szabo E. Higher levels of the anti-inflammatory protein CC10 are associated with improvement in bronchial dysplasia and sputum cytometric assessment in individuals at high risk for lung cancer. Clin Cancer Res. (In press.)

Reid JM, Mandrekar SJ, Cadson EC, Narmsen WS, Green E, McGovern RM, Szabo E, Ames MM, Boring D, Limburg P. Compatative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev. (In press.)

Smith JJ, Berg CD. Lung cancer screening: promise and practice. Seminars in Oncology Nursing. 2008 24:9-15.

Szabo, E. First do no harm: when is it appropriate to plan a cancer prevention clinical trial? Nature Clin Practice Oncol. (In press.)

Szabo E. Assessing efficacy in early phase cancer prevention trials: The case of oral premalignancy. Cancer Prev Res (in press).

2007

Chen J, Lam S, Pilon A, McWilliams A, MeJby I, Szabo E. The association between the anti-inflammatoly protein CC10 and smoking status among participants in a chemopevention trial. Cancer Epidemiol Biomarkers Prev. 2007 16:577-83.

Kelloff GJ, Suflivan DC, Baker H, et al. Workshop on Imaging science development for cancer prevention and preemption. Cancer Biomark. 2007 3:1-33.

Rhoden J, Mao JT, Szabo E, Kelley M, Kurie J, Bepler S. Lung cancer chemoprevention —an ACOP evidence-based clinical practice guideline. Chest. 2007. 132:56-68.

Szabo E. Proliferative changes in chermoprevention trials: learning from secondary endpoints. J Natl Cancer Inst. 2007 99:1555-1567.